Literature DB >> 27090959

Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.

R Grant Rowe1, Dongjing Guo2, Michelle Lee3, Steven Margossian3, Wendy B London3, Leslie Lehmann4.   

Abstract

Cytomegalovirus (CMV) infection is a significant source of morbidity and mortality in allogeneic stem cell transplantation (SCT). We identified a cohort of 91 pediatric SCT patients at risk (defined as either donor and/or recipient seropositivity) for CMV infection at our institution. We retrospectively categorized at-risk SCT recipients as those who (1) were at risk of CMV infection in the post-SCT period, (2) had documented CMV infection before SCT, (3) experienced recurrence of post-SCT CMV viremia, or (4) experienced late post-SCT CMV viremia; categories were not mutually exclusive. We analyzed the impact of SCT-related factors on incidence of CMV infection and outcome, and we described the outcome of each of these cohorts. In univariate analysis, recipient CMV seropositivity, use of umbilical cord blood graft, and acute graft-versus-host disease (GVHD) predicted post-SCT CMV viremia, and the effects of acute GVHD (odds ratio, 4.018; 95% confidence interval, 1.032 to 15.643) and CMV seropositivity (odds ratio, 16.525; 95% confidence interval, 2.041 to 133.803) were confirmed in multivariate analysis. Patients with recurrence of post-SCT CMV viremia had a 50% all-cause mortality rate, compared with 12% in all 91 patients. Patients with pre-SCT CMV infection had a high incidence of post-SCT CMV infection but could successfully undergo SCT with antiviral prophylaxis and pre-emptive CMV treatment. All patients with late CMV infection had prior GVHD. Theses findings identify risk factors for post-SCT CMV infection and provide novel descriptions of childhood SCT recipients with pre-SCT, recurrent, and late CMV infection, which may contribute to risk stratification strategies for CMV at-risk patients in pediatric allogeneic SCT.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytomegalovirus; Graft-versus host disease; Umbilical cord transplant

Mesh:

Substances:

Year:  2016        PMID: 27090959      PMCID: PMC5491305          DOI: 10.1016/j.bbmt.2016.04.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  33 in total

1.  Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.

Authors:  H Einsele; H Hebart; C Kauffmann-Schneider; C Sinzger; G Jahn; P Bader; T Klingebiel; K Dietz; J Löffler; C Bokemeyer; C A Müller; L Kanz
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

2.  CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.

Authors:  Yvonne Suessmuth; Rithun Mukherjee; Benjamin Watkins; Divya T Koura; Knut Finstermeier; Cindy Desmarais; Linda Stempora; John T Horan; Amelia Langston; Muna Qayed; Hanna J Khoury; Audrey Grizzle; Jennifer A Cheeseman; Jason A Conger; Jennifer Robertson; Aneesah Garrett; Allan D Kirk; Edmund K Waller; Bruce R Blazar; Aneesh K Mehta; Harlan S Robins; Leslie S Kean
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

3.  A single-center experience of cytomegalovirus infections in Asian pediatric patients undergoing allogeneic hematopoietic stem cell transplant for leukemia in Singapore.

Authors:  P L Tan; L M Lim; C Khanlian; M S Villegas
Journal:  Transpl Infect Dis       Date:  2014-05-23       Impact factor: 2.228

4.  High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

Authors:  Suparno Chakrabarti; Stephen Mackinnon; Raj Chopra; Panagiotis D Kottaridis; Karl Peggs; Peter O'Gorman; Ronjon Chakraverty; Timothy Marshall; Husam Osman; Premini Mahendra; Charles Craddock; Herman Waldmann; Geoff Hale; Christopher D Fegan; Kwee Yong; Anthony H Goldstone; David C Linch; Donald W Milligan
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.

Authors:  Pierre Reusser; Hermann Einsele; John Lee; Liisa Volin; Montserrat Rovira; Dan Engelhard; Jürgen Finke; Catherine Cordonnier; Hartmut Link; Per Ljungman
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

Review 6.  Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.

Authors:  Ella J Ariza-Heredia; Lior Nesher; Roy F Chemaly
Journal:  Cancer Lett       Date:  2013-09-13       Impact factor: 8.679

7.  Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial.

Authors:  D J Winston; W G Ho; K Bartoni; C Du Mond; D F Ebeling; W C Buhles; R E Champlin
Journal:  Ann Intern Med       Date:  1993-02-01       Impact factor: 25.391

8.  Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.

Authors:  Christopher M Walker; Jo-Anne H van Burik; Todd E De For; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2007-09       Impact factor: 5.742

9.  Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group.

Authors:  H G Prentice; E Gluckman; R L Powles; P Ljungman; N Milpied; J M Fernandez Rañada; F Mandelli; P Kho; L Kennedy; A R Bell
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

10.  Predictive factors of cytomegalovirus seropositivity among pregnant women in Paris, France.

Authors:  Dieynaba S N'Diaye; Yazdan Yazdanpanah; Anne Krivine; Thibaut Andrieu; Flore Rozenberg; Olivier Picone; Vassilis Tsatsaris; François Goffinet; Odile Launay
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

View more
  4 in total

Review 1.  Early pulmonary complications related to cancer treatment in children.

Authors:  Cara E Morin; Morgan P McBee; Lama Elbahlawan; Lindsay M Griffin; Gabriela M Maron; HaiThuy N Nguyen; Akshay Sharma; Elizabeth J Snyder; Jean Jeudy
Journal:  Pediatr Radiol       Date:  2022-07-02

2.  Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.

Authors:  Matt S Zinter; Brent R Logan; Caitrin Fretham; Anil Sapru; Allistair Abraham; Mahmoud D Aljurf; Staci D Arnold; Andrew Artz; Jeffery J Auletta; Saurabh Chhabra; Edward Copelan; Christine Duncan; Robert P Gale; Eva Guinan; Peiman Hematti; Amy K Keating; David I Marks; Richard Olsson; Bipin N Savani; Celalettin Ustun; Kirsten M Williams; Marcelo C Pasquini; Christopher C Dvorak
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-26       Impact factor: 5.742

3.  Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy.

Authors:  Umberto Restelli; Davide Croce; Valeria Pacelli; Fabio Ciceri; Corrado Girmenia
Journal:  Infect Drug Resist       Date:  2019-05-08       Impact factor: 4.003

4.  The Impact of High CMV Viral Load and Refractory CMV Infection on Pediatric HSCT Recipients with Underlying Non-Malignant Disorder.

Authors:  Zofia Szmit; Jowita Frączkiewicz; Małgorzata Salamonowicz-Bodzioch; Anna Król; Marek Ussowicz; Monika Mielcarek-Siedziuk; Karolina Liszka; Paweł Marschollek; Ewa Gorczyńska; Krzysztof Kałwak
Journal:  J Clin Med       Date:  2022-09-01       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.